Pill Identifier App

Journal of Drugs in Dermatology Highlights Data Showing the Benefits of Solubilized 5% Benzoyl Peroxide Gel in the Treatment of Acne

LONG BEACH, Calif.--(BUSINESS WIRE)--Jun 16, 2008 - Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin health systems, announced today the publication of a study of its solubilized 5% BPO gel in the June 2008 issue of Journal of Drugs in Dermatology. When compared to twice-daily treatment with a leading BPO/clindamycin antibiotic combination product, the twice-daily monotherapy with the solubilized 5% BPO gel resulted in faster reductions in non-inflammatory and inflammatory lesions. Data shows a significantly greater reduction of non-inflammatory lesions at week 1 and a significantly greater reduction of inflammatory lesions at week 4, with both time points being statistically significant. Both regimens were well-tolerated with comparable levels of patient satisfaction.

"The data show that the solubilized BPO gel is effective in treating acne, particularly comedonal acne which has traditionally been difficult to treat rapidly," said Emil Tanghetti, MD, Center for Dermatology and Laser Surgery, Sacramento, California, and lead investigator of the study. "This is a significant advancement in benzoyl peroxide technology because by enhancing delivery to the source of acne, the treatment is effective while eliminating the need for antibiotics that are a key component of other treatments."

The Obagi Medical Products solubilized 5% BPO gel is clinically proven to aid in the follicular penetration of BPO. Traditional BPO formulations are poorly soluble, existing primarily as micro and macrocrystals, some of which are too large to enter the follicles and treat acne at the source.

"Obagi Medical's solubilized BPO technology has allowed us to improve upon the treatment of acne, a condition that affects nearly 17 million people in the U.S.," said Steven Carlson, Chief Executive Officer of Obagi Medical Products. "With the growing issue of antibiotic resistance, creating this technology that penetrates the follicle and reduces acne flare-ups quickly and effectively without the need for antibiotics puts Obagi at the forefront of dermatological advances in acne treatment."

Data and Methodology

Patients were assigned to receive treatment with the solubilized 5% BPO gel on one side of their face and the 5% BPO/1% clindamycin combination products on the contralateral side of their face, twice daily for 4 weeks. -0-

                       NON-INFLAMMATORY LESIONS

TREATMENT                   WEEK 1 REDUCTION       WEEK 4 REDUCTION

----------------------- ------------------------ ---------------------

5% Solubilized BPO gel    26% (P less than or

                              equal to .05)               42%

----------------------- ------------------------ ---------------------

5% BPO/1% clindamycin              3%                     28%

----------------------- ------------------------ ---------------------

-0-
                         INFLAMMATORY LESIONS

TREATMENT                WEEK 1 REDUCTION        WEEK 4 REDUCTION

---------------------- -------------------- --------------------------

5% Solubilized BPO gel                      70% (P less than or equal

                               35%                    to .05)

---------------------- -------------------- --------------------------

5% BPO/1% clindamycin          35%                     61%

---------------------- -------------------- --------------------------

About Solubilized Benzoyl Peroxide

Obagi Medical's proprietary, solubilized BPO, known as SoluZyl Technology, is 1/10,000 the size of any other benzoyl peroxide molecule available, so it can penetrate deep into the root of the follicle and treat acne where it starts. Obagi Medical's solubilized 5% BPO is clinically proven to kill more P. acnes bacteria faster than the leading gel BPO/antibiotic combination product.

The solubilized BPO is available in both gel and lotion forms and can be purchased individually or as part of a CLENZIderm M.D. Acne Therapeutic System. The Systems come in two formulations, one for normal to oily skin patients (Gel) and one for normal to dry skin patients (Lotion).

The CLENZIderm M.D. Systems are not available over the counter and can only be obtained through physician offices.

About Obagi Medical Products, Inc.

Obagi Medical Products develops and commercializes skin health products for the dermatology, plastic surgery, and related aesthetic markets. Using its Penetrating Therapeutics(TM) technologies, Obagi Medical's products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including chloasma, melasma, senile lentigines, acne vulgaris and sun damage. The history of Obagi's skin care product introductions is as follows: Obagi Nu-Derm(R), 1988; Obagi-C(R) Rx (the first and only prescription-strength vitamin C and hydroquinone system), 2004; Obagi(R) Professional-C (a line of highly stable vitamin C serums), 2005; Obagi(R) Condition and Enhance for use with cosmetic procedures to enhance patient outcomes and satisfaction, 2006; Obagi ELASTIderm(TM) eye treatment and Obagi CLENZIderm(R) M.D. acne therapeutic systems, 2007; a formulation of Obagi CLENZIderm(R) M.D. Systems for normal to dry skin, June 2007; and Obagi ELASTIderm(TM) Decolletage System, January 2008. Obagi's products are only available through physicians. Visit www.obagi.com for information.

Forward Looking Statements

There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should," "potential," "anticipates," "plans," or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to the intense competition our products face and will face in the future, the level of market acceptance of our products, the possibility that our products could be rendered obsolete by technological or medical advances, the possibility that we may become involved in intellectual property claims and litigation that could adversely affect the profitability of or our ability to sell our products, the possibility that our products may cause undesirable side effects and the fact that our ability to commercially distribute our products may be significantly harmed if the regulatory environment governing our products changes. A more detailed discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our Form 10-K for the year ended December 31, 2007. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Obagi Medical Products does not intend to update this information.

Contact

Obagi Medical Products
Investor Contact:
Ina McGuinness or Lena Adams
ICR, Inc.
(o) 310-954-1100
or
Media Contact:
HealthSTAR Public Relations
(o) 646-722-8839
scoughlin@healthstarpr.com
Shannon Coughlin

Posted: June 2008

View comments

Hide
(web4)